Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.

Schütt P, Zimmermann K, Derks C, Ebeling P, Welt A, Poser M, Hense J, Metz K, Anhuf J, Sandmann M, Neise M, Moritz T, Stuschke M, Niederle N, Seeber S, Nowrousian MR.

J Cancer Res Clin Oncol. 2009 Mar;135(3):459-66. doi: 10.1007/s00432-008-0467-2. Epub 2008 Aug 29.

PMID:
18758815
2.

The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.

Schütt P, Rebmann V, Brandhorst D, Wiefelspütz J, Ebeling P, Opalka B, Seeber S, Nowrousian MR, Moritz T, Grosse-Wilde H.

Hum Immunol. 2008 Feb;69(2):79-87. doi: 10.1016/j.humimm.2008.01.006. Epub 2008 Feb 7.

PMID:
18361931
3.

Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.

Nowrousian MR, Dunst J, Vaupel P.

Strahlenther Onkol. 2008 Mar;184(3):121-36. doi: 10.1007/s00066-008-1841-3. Review.

PMID:
18330508
4.

Diagnostic yield of computed tomography-guided coaxial core biopsy of undetermined masses in the free retroperitoneal space: single-center experience.

Stattaus J, Kalkmann J, Kuehl H, Metz KA, Nowrousian MR, Forsting M, Ladd SC.

Cardiovasc Intervent Radiol. 2008 Sep-Oct;31(5):919-25. doi: 10.1007/s00270-008-9317-5. Epub 2008 Mar 6.

PMID:
18322731
5.

Long-term results of a phase-I/II study of sequential high-dose chemotherapy with autologous stem cell transplantation in the initial treatment of aggressive non-Hodgkin's lymphoma.

Welt A, Schütt P, Derks C, Ebeling P, Müller S, Metz K, Anhuf J, Moritz T, Seeber S, Nowrousian MR.

Tumori. 2007 Sep-Oct;93(5):409-16.

PMID:
18038870
6.
7.

Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.

Rebmann V, Schütt P, Brandhorst D, Opalka B, Moritz T, Nowrousian MR, Grosse-Wilde H.

Clin Immunol. 2007 Apr;123(1):114-20. Epub 2007 Jan 10.

PMID:
17218152
8.

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.

Schütt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S, Buttkereit U, Opalka B, Lindemann M, Grosse-Wilde H, Seeber S, Moritz T, Nowrousian MR.

Leuk Lymphoma. 2006 Aug;47(8):1570-82.

PMID:
16966269
9.

Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis.

Boogaerts M, Oberhoff C, Ten Bokkel Huinink W, Nowrousian MR, Hayward CR, Burger HU.

Anticancer Res. 2006 Jan-Feb;26(1B):479-84.

10.

Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy".

Nowrousian MR.

Oncologist. 2006 May;11(5):535-6; author reply 536-7. No abstract available.

11.

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.

Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Bradwell AR, Buttkereit U, Opalka B, Flasshove M, Moritz T, Seeber S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8706-14.

12.

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.

Schütt P, Buttkereit U, Brandhorst D, Lindemann M, Schmiedl S, Grosse-Wilde H, Seeber S, Nowrousian MR, Opalka B, Moritz T.

Cancer Immunol Immunother. 2005 May;54(5):506-12. Epub 2004 Nov 20.

PMID:
15750834
13.

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR.

Ann Hematol. 2005 Sep;84(9):594-600. Epub 2005 Mar 3.

PMID:
15744524
14.

Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation.

Lindemann M, Schuett P, Moritz T, Ottinger HD, Opalka B, Seeber S, Nowrousian MR, Grosse-Wilde H.

Leukemia. 2005 Mar;19(3):490-2. No abstract available.

PMID:
15674357
15.

Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.

Korfel A, Martus P, Nowrousian MR, Hossfeld DK, Kirchen H, Brücher J, Stelljes M, Birkmann J, Peschel C, Pasold R, Fischer L, Jahnke K, Thiel E; German primary central nervous system lymphoma Study Group (G-PCNSL-SG).

Br J Haematol. 2005 Jan;128(2):177-83.

PMID:
15638851
16.

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR.

Eur J Haematol. 2005 Jan;74(1):40-6.

PMID:
15613105
17.

Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.

Müller S, Schütt P, Bojko P, Nowrousian MR, Hense J, Seeber S, Moritz T.

Ann Hematol. 2005 Feb;84(2):110-4. Epub 2004 Sep 1.

PMID:
15340761
18.

FDG-PET/CT in re-staging of patients with lymphoma.

Freudenberg LS, Antoch G, Schütt P, Beyer T, Jentzen W, Müller SP, Görges R, Nowrousian MR, Bockisch A, Debatin JF.

Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):325-9. Epub 2003 Nov 26.

PMID:
14647988
19.

Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).

Link H, Böhme A, Cornely OA, Höffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW; Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO); Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).

Ann Hematol. 2003 Oct;82 Suppl 2:S105-17. Epub 2003 Sep 9.

PMID:
13680173
20.

Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.

Nowrousian MR, Waschke S, Bojko P, Welt A, Schuett P, Ebeling P, Flasshove M, Moritz T, Schuette J, Seeber S.

Ann Oncol. 2003;14 Suppl 1:i29-36.

PMID:
12736228
21.

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.

Fosså A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, Bonadonna G, Seeber S, Nowrousian MR.

J Clin Oncol. 1999 Dec;17(12):3786-92.

PMID:
10577850
22.

Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma.

Fosså A, Brandhorst D, Myklebust JH, Seeber S, Nowrousian MR.

Exp Hematol. 1999 Nov;27(11):1621-6.

PMID:
10560909
23.

[Antimicrobial therapy for fever of unknown origin in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology].

Link H, Blumenstengel K, Böhme A, Cornely O, Kellner O, Nowrousian MR, Ostermann H, Schiel X, Wilhelm M.

Dtsch Med Wochenschr. 1999 Apr 9;124 Suppl 1:S3-8. German. No abstract available.

PMID:
10410648
24.

Recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia.

Nowrousian MR.

Med Oncol. 1998 Sep;15(3):141-4. No abstract available.

PMID:
9819790
26.

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study.

Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H.

Ann Oncol. 1998 Mar;9(3):255-60.

PMID:
9602258
27.
28.
29.

Recurrence of Hodgkin's disease after 10 or more years: late relapse or de-novo malignancy due to HLA-DPB1*0301-linked susceptibility?

Siebert R, Fosså A, Kaiser W, Welt A, Ferencik S, Seeber S, Nowrousian MR.

Leuk Lymphoma. 1997 Jun;26(1-2):121-5.

PMID:
9250796
30.

Recombinant human erythropoietin in the treatment of cancer-related anaemia.

Kasper C, Terhaar A, Fosså A, Welt A, Seeber S, Nowrousian MR.

Eur J Haematol. 1997 Apr;58(4):251-6.

PMID:
9186536
31.

BCR rearrangement without juxtaposition of ABL in pre-T acute lymphoblastic leukaemia.

Fosså A, Siebert R, Kasper C, Becher R, Opalka B, Thiel E, Seeber S, Nowrousian MR.

Br J Haematol. 1996 May;93(2):403-5.

PMID:
8639438
32.

Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines.

Siebert R, Willers CP, Fosså A, Kloke O, Nowrousian MR, Seeber S, Opalka B.

Leuk Res. 1996 Feb;20(2):197-200.

PMID:
8628020
33.

Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.

Siebert R, Willers CP, Schramm A, Fosså A, Dresen IM, Uppenkamp M, Nowrousian MR, Seeber S, Opalka B.

Br J Haematol. 1995 Oct;91(2):350-4.

PMID:
8547074
34.

D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport.

Pohl J, Bertram B, Hilgard P, Nowrousian MR, Stüben J, Wiessler M.

Cancer Chemother Pharmacol. 1995;35(5):364-70.

PMID:
7850916
35.

Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis.

Müller MR, Lennartz K, Nowrousian MR, Dux R, Tsuruo T, Rajewsky MF, Seeber S.

Cytometry. 1994 Jan 1;15(1):64-72.

36.

Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.

Müller MR, Lennartz K, Boogen C, Nowrousian MR, Rajewsky MF, Seeber S.

Ann Hematol. 1992 Nov;65(5):206-12.

PMID:
1360820
37.

Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.

Nowrousian MR, Anders CH, Niederle N, Nagel-Hiemke M, Moritz T, Seeber S, Schmidt CG.

Ann Oncol. 1991 Jan;2 Suppl 1:25-30.

PMID:
1710486
38.

[Chemotherapy of nonendemic Burkitt's lymphoma].

Kath R, Höffken K, Günzel K, Nowrousian MR, Donhuijsen K, Anders CU, Sack H, Schmidt CG.

Dtsch Med Wochenschr. 1990 Aug 17;115(33):1219-26. German.

PMID:
2387214
39.

Nitrosoureas. Modes of action and perspectives in the use of hormone receptor affinity carrier molecules.

Eisenbrand G, Berger MR, Brix HP, Fischer JE, Mühlbauer K, Nowrousian MR, Przybilski M, Schneider MR, Stahl W, Tang W, et al.

Acta Oncol. 1989;28(2):203-11. Review.

PMID:
2544212
40.

Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.

Nowrousian MR, Meier CR, Schoetensack B, Anders C, Höffken K, Osieka R, Schmidt CG.

Acta Oncol. 1989;28(4):495-500.

PMID:
2477048
41.

Acute myelocytic leukemia in adults: a long-term analysis.

Nowrousian MR, Kubaschinski G, Pfeiffer R, Schaefer UW, Schmidt CG.

Haematol Blood Transfus. 1987;30:373-5. No abstract available.

PMID:
3476369
42.

Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia.

Nowrousian MR, Pfeiffer R, Schaefer UW, Osieka R, Niederle N, Anders C, Schmidt CG.

Haematol Blood Transfus. 1987;30:352-5. No abstract available.

PMID:
3305206
43.

Reversed-phase high-performance liquid chromatographic determination of anaxirone in biological specimens.

Schilcher RB, Young JD, Nowrousian MR, Hoffmann B, Schmidt CG.

J Chromatogr. 1986 May 28;378(1):248-53. No abstract available.

PMID:
3733978
44.

[High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].

Nowrousian MR, Seeber S, Miller AA, Anders C, Ohl S, Schmidt CG.

Onkologie. 1985 Feb;8(1):26-32. German.

PMID:
3885117
45.

[Bone marrow transplantation in panmyelopathies and leukemias with special regard to gnotobiotic measures].

Schaefer UW, Mahmoud HK, Schüning F, Schmidt CG, Becher R, Nowrousian MR, Ohl S, Wetter O, Bamberg M, Alberti W, et al.

Dtsch Med Wochenschr. 1984 Dec 14;109(50):1909-13. German.

PMID:
6391886
46.
47.

[Results of treatment of acute myeloid leukemia in adults].

Nowrousian MR, Kubaschinski G, Hossfeld DK, Schaefer UW, Schmidt CG.

Onkologie. 1983 Aug;6(4):184-6. German.

PMID:
6355947
48.

Effects of cisplatin on different haemopoietic progenitor cells in mice.

Nowrousian MR, Schmidt CG.

Br J Cancer. 1982 Sep;46(3):397-402.

49.

[Bone marrow transplantation for aplastic anaemia and acute leukaemia (author's transl)].

Schaefer UW, Schmidt CG, Rüther U, Schüning F, Becher R, Beyer JH, Hossfeld DK, Nowrousian MR, Ohl S, Wetter O, Bamberg M, Schmitt G, Bormann U, Scherer E, Haralambie E, Linzenmeier G, Grosse-Wilde H, Hierholzer E, Kuwert E, Henneberg KB, Luboldt W, Richter HJ, Leder LD, Hantschke D.

Dtsch Med Wochenschr. 1982 May 28;107(21):803-8. German.

PMID:
7042268
50.

Multicentre study on intensified remission induction therapy for acute myeloid leukemia.

Büchner T, Urbanitz D, Emmerich B, Fischer JT, Fülle HH, Heinecke A, Hossfeld DK, Koeppen KM, Labedzki L, Löffler H, Nowrousian MR, Pfreundschuh M, Pralle H, Rühl H, Wendt FC.

Leuk Res. 1982;6(6):827-31.

PMID:
6961273

Supplemental Content

Loading ...
Support Center